Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Gains from Sales and Divestitures (2019 - 2025)

Cyclerion Therapeutics (CYCN) has 7 years of Gains from Sales and Divestitures data on record, last reported at $45072.0 in Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures fell 20.56% year-over-year to $45072.0; the TTM value through Sep 2025 reached $45072.0, down 20.56%, while the annual FY2024 figure was $71763.0, 30.48% up from the prior year.
  • Gains from Sales and Divestitures reached $45072.0 in Q3 2025 per CYCN's latest filing, up from $30048.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $143774.0 in Q4 2021 and bottomed at $3375.0 in Q2 2023.
  • Average Gains from Sales and Divestitures over 5 years is $49890.1, with a median of $45072.0 recorded in 2025.
  • Peak YoY movement for Gains from Sales and Divestitures: crashed 91.49% in 2023, then soared 1136.0% in 2024.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $143774.0 in 2021, then tumbled by 62.44% to $53999.0 in 2022, then grew by 1.85% to $55000.0 in 2023, then soared by 30.48% to $71763.0 in 2024, then crashed by 37.19% to $45072.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $45072.0 in Q3 2025, $30048.0 in Q2 2025, and $15024.0 in Q1 2025.